Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
TA

NASDAQ · TARS

Tarsus Pharmaceuticals, Inc. Common Stock

Healthcare · Biotechnology

$74.11

Down-$0.35 (-0.46%)

Updated Oct 7, 2026, 5:21 AM

SID Score

4.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.47B
P/E ratio
-42.92
Dividend yield
0.00%
52-week range
$53.89 – $91.53
Volume
432.43K
Avg. volume
558K

Price performance · TARS

TARS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

TARS closed at $74.11 after 21 trading sessions, down 15.03% for the selected period.

Last close
$74.11
Period change
-15.03%
Period low
$73.00
Period high
$87.22
Daily close
View OHLC price history
TARS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$74.48$75.255$72.94$74.11432.43K
Oct 5, 2026$73.22$75.00$72.76$74.455939.61K
Oct 2, 2026$75.84$75.84$72.94$73.001.21M
Oct 1, 2026$78.45$79.10$75.03$75.461.24M
Sep 30, 2026$76.76$78.70$76.315$78.611.56M
Sep 29, 2026$76.22$77.9872$75.53$76.69417.97K
Sep 28, 2026$75.83$76.8195$74.6601$76.811.31M
Sep 25, 2026$75.78$76.17$73.8501$75.69721.44K
Sep 24, 2026$75.33$77.91$74.44$75.96598.79K
Sep 23, 2026$77.18$77.6061$74.20$74.29674.31K
Sep 22, 2026$77.61$78.5925$76.01$77.08517.02K
Sep 21, 2026$78.09$78.57$76.39$77.46487.11K
Sep 18, 2026$78.67$79.10$77.33$78.09710.97K
Sep 17, 2026$78.55$79.78$77.29$79.03474.86K
Sep 16, 2026$78.38$79.75$77.08$77.64658.81K
Sep 15, 2026$80.01$80.01$77.77$78.23623.99K
Sep 14, 2026$79.69$80.235$78.40$79.95693.7K
Sep 11, 2026$82.27$83.225$79.175$79.31490.79K
Sep 10, 2026$80.892$83.34$80.81$81.12403.28K
Sep 9, 2026$86.31$87.31$82.67$82.77565.45K
Sep 8, 2026$89.67$90.75$87.01$87.221.82M

Latest TARS news

The latest Smart Investors Daily articles mentioning TARS.

Stock researchCompany · Overview

TARS research

Overview

Company profile and research snapshot.

Company profile

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$84.75
Implied upside
—
Analysts
—
TARS recent ratings
DateFirmRatingTarget
Sep 24, 2026Goldman SachsBuy—
Sep 16, 2026BarclaysOverweight—
Sep 8, 2026JefferiesBuy—
Aug 12, 2026OppenheimerOutperform—
Jul 31, 2026MizuhoOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California. The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY® (lotilaner ophthalmic solution) 0.25%; and the pr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By